Treatment Goals and Evolving Patient Conversations in Small Cell Lung Cancer

Immune checkpoint inhibitors have transformed frontline care for metastatic melanoma, but a substantial proportion of patients do not achieve durable disease control, which leaves a clear unmet need after progression. In this segment, the panel examines how treatment decisions unfold once frontline immunotherapy stops working. For patients with BRAF-mutant disease, BRAF/MEK inhibitors remain an option. The faculty note, however, that durable benefit with targeted therapy is uncommon, and several prefer to hold these agents in reserve unless rapid progression, declining performance status, or rising symptom burden calls for a quick response. The discussion highlights how the frontline regimen shapes the next step. Patients who received nivolumab plus relatlimab may be considered for ipilimumab plus nivolumab before more intensive options, while fit patients may move toward cellular therapy, with targeted therapy serving as a bridge when needed. The panel also emphasizes clinical trial enrollment, because responses to immunotherapy tend to be more durable than responses to targeted agents.